proseedmag: the MIT Enterprise Forum Poland program aims to speed up the development of recently-established tech companies. It accomplishes this by connecting these innovators with the know-how, experience and assets of leading corporations, investment funds as well as various other organizations from Poland and around the world. Nearly 100 startups have already received a much-needed boost from the accelerator program. Łukasz Owczarek, Head of Acceleration at the Technological Entrepreneurship Foundation which is organizing the program, says that there are still plenty of ground-breaking, youthful companies in Poland – players that absolutely have the potential to conquer foreign markets – provided they receive the right kind of support at the beginning of their journey.
Bioceltix: utilizing the immunomodulatory properties of stem cells in order to treat typical autoimmune conditions in animals. The company creates biopharmaceuticals which offer several advantages versus traditional pharmacology.
Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...Article
Forbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...Article
According to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...Article
Gazeta Wrocławska wrote about us: “Bioceltix is working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...Article
We create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...Article
All of the stem-cell-based biopharmaceuticals being developed by our company are designed to treat conditions caused by chronic inflammatory ...Read full
The gala that concluded the 8th edition of this ranking took place on June 27th at Warsaw’s Multikino Złote Tarasy. This time the event was ...Read full
Gazeta Wrocławska: Bioceltix develops biological drugs for common pet diseases. At the moment, the company is working on drugs for locomotor ...Read full